Entacapone 200mg/tablet (f.c).
It is a chocolate-o-methyl transferase inhibitor.

Ind: Adjunct to levodopa/benserazide or levodopa/carbidopa treatment in patients with Parkinson's disease and end-of dose motor fluctuations, who cannot be stabilised on those combinations.

C/I: Known hypersensitivity to entacapone or any of the excipients. Pregnancy and breastfeeding. Liver impairment. Phaeochromocytoma. Concomitant use with nonselective monoamine oxidase inhibitors (MAO-A and MAO-B). Concomitant use with a selective MAO-A plus a selective MAO-B inhibitor. History of neuroleptic malignant syndrome (NMS) and/or nontraumatic rhabdomyolysis.

AIR: Dyskinesia; gastrointestinal symptoms ( e.g nausea, vomiting, abdominal pain, constipation, diarrhoea, dry mouth); discoloration of urine; fatigue, insomnia, paroniria, confusion, hallucinations; dizziness, postural hypotension, vertigo, headache; leg cramps, hyperkinesia, tremor, increased sweating; slight decrease in hemoglobin,
erythrocyte count, and haematocrit. Increases in liver enzymes have been reported rarely. Precautions & warnings: Dosage of levodopa and other antiparkinsonian medications ( e.g dopamine agonists) may need to be adjusted
when entacapone treatment is initiated. Levodopa-induced orthostatic hypotension may be aggravated. Effects of medicinal products metabolised by catechol-o-methyl transferase may be potentiated. Caution when discontinuing
entacapone treatment (see full prescribing information).

Dosage: 200mg with each levodopa/dopadecarboxylase inhibitor dose. Maximum recommended daily dose is 2000mg.

Drug inter: Entacapone and iron preparations should be taken at least 2-3 hours apart.
30's pack: 2474.40 MRP

Note: For further information consult full prescribing information.